ibs and glp 1 semaglutide 🔎Real-world data on GLP-1RA switching & discontinuation in IBS pts Centrally administered GLP-1 analogue improves

Some formulations now affect both GLP-1 and GIP pathways, addressing multiple aspects of weight regulation at once

A significant drug main effect, but no drug time-point effects, was found on blood total ghrelin concentrations

Forcing often leads to unwanted side effects and imbalance (not homeostasis)

Clinically, semaglutide 2.4 mg not only helps weight loss but also improves cardiovascular risk factors (blood pressure, lipids) and physical function in patients with obesity

Additionally, cost-effectiveness analyses have shown that current GLP-1 pricing does not align with accepted value thresholds, making health systems less likely to support broad reimbursement